Drug intelligence / Profile preview

HF60

Development stage: Preclinical
Lead developer: HighField Biopharmaceuticals
Modality: Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

HF60 is a preclinical-stage T cell engager complex being developed by HighField Biopharmaceuticals for the treatment of autoimmune diseases. As a T cell engager, it is designed to redirect T cell activity to modulate immune responses or deplete pathogenic cell populations associated with autoimmune conditions. While the specific molecular targets and payload details have not been disclosed, the asset represents HighField's expansion of its immunotherapy platform into the autoimmune space.

Beyond the preview

Go deeper on HF60.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HF60.

Explore the full profile